Company Overview

CVRx, Inc. is a medical device company focused on developing and commercializing neuromodulation therapies for the treatment of cardiovascular diseases, primarily heart failure. The company operates within the cardiovascular medical devices and electroceuticals segments of the broader healthcare industry. Its core product is the Barostim™ Therapy system, an implantable device designed to deliver electrical pulses to the carotid baroreceptors to regulate the autonomic nervous system in patients with chronic heart failure.

The company’s primary revenue driver is the sale of Barostim™ Therapy systems and related accessories, along with associated procedural and support services. CVRx primarily serves hospitals, cardiologists, electrophysiologists, and heart failure specialists, targeting patients with heart failure with reduced ejection fraction who remain symptomatic despite guideline-directed medical therapy. CVRx is positioned as a first mover in its category, with Barostim™ Therapy being the first FDA-approved neuromodulation device for heart failure. The company was founded in 2000 and transitioned from a development-stage enterprise to a commercial-stage company following U.S. regulatory approval and its subsequent initial public offering.

Business Operations

CVRx operates as a single operating and reportable segment, focused exclusively on the development, manufacturing, and commercialization of Barostim™ Therapy. Revenue is generated primarily through direct sales of implantable pulse generators, leads, and related system components, as well as limited service-related revenue. The company maintains direct sales operations in the United States, which represents its largest market, supported by clinical education and reimbursement-focused teams.

Internationally, CVRx sells Barostim™ Therapy through a combination of direct operations and distributors in select markets, primarily in Europe. The company controls its proprietary neuromodulation technology, including patented device designs and stimulation algorithms. CVRx does not report multiple business units or diversified product lines, and it does not rely on significant joint ventures; operations are conducted primarily through the parent company without material operating subsidiaries.

Strategic Position & Investments

CVRx’s strategic direction centers on expanding adoption of Barostim™ Therapy for heart failure by increasing physician awareness, strengthening reimbursement coverage, and generating additional clinical evidence. Growth initiatives include expanding the U.S. commercial sales force, increasing implanting center penetration, and pursuing broader payer coverage, including Medicare and commercial insurers. The company continues to invest in post-approval clinical studies to support long-term outcomes and economic value propositions.

The company’s investment activity has been focused on internal research and development rather than large-scale acquisitions. CVRx continues to refine its core technology platform and explore next-generation device enhancements within the neuromodulation and cardio-renal therapeutic landscape. Public disclosures indicate no material acquisitions or diversified investment portfolios, with strategic resources concentrated on scaling its flagship therapy.

Geographic Footprint

CVRx is headquartered in Minneapolis, Minnesota, a major U.S. medical device hub. Its primary commercial operations are in North America, where the majority of revenue is generated. The company also maintains a presence in Europe, including operations and distributor-supported sales in countries such as Germany and other select European markets.

Manufacturing, clinical support, and administrative functions are primarily based in the United States, with international activities focused on commercialization rather than large-scale production. While CVRx’s global footprint is narrower than that of large multinational device companies, its international presence is strategically targeted to markets with established reimbursement pathways and advanced heart failure care infrastructure.

Leadership & Governance

CVRx is led by an executive team with experience in medical device commercialization, regulatory strategy, and cardiovascular therapies. The leadership emphasizes clinical evidence generation, disciplined commercialization, and long-term value creation through focused execution in a specialized therapeutic category.

Key executives include:

• Kevin Hykes – President and Chief Executive Officer
• Scott Crutchfield – Chief Financial Officer
• Justin Ketcham – Chief Technology Officer
• Nick Trigsted – Chief Operating Officer

The company is governed by a board of directors with backgrounds in medical technology, healthcare investing, and corporate governance, aligning oversight with CVRx’s strategy as a focused, growth-oriented cardiovascular device company.